Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 145,139 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder Clear all
Active, not recruiting Early Phase 1 Interventional

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

NCT05477823
View directory record Official record
Conditions
Prostate Cancer
Interventions
External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Radiation · Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 28, 2026, 1:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)

NCT06940323
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome, NMOSD, Myasthenia Gravis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2035
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 1:33 AM EDT
Completed No phase listed Observational

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

NCT02953223
View directory record Official record
Conditions
Cow's Milk Protein Allergy, Eosinophilic Gastrointestinal Disorders, Malabsorption/Maldigestion, Short Bowel Syndrome, Multiple Food Allergies
Interventions
Free amino acid infant formula
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
1 Day to 12 Months
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Lakeside, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study of Zagociguat in Patients With MELAS

NCT06402123
View directory record Official record
Conditions
Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions
zagociguat 15mg, zagociguat 30mg, Placebo
Drug
Lead sponsor
Tisento Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Instrument Assisted Soft Tissue Mobilization Effect on Blood Flow

NCT04785079
View directory record Official record
Conditions
Asymptomatic Condition
Interventions
Graston Instrument assisted Soft tissue Mobilization
Procedure
Lead sponsor
Florida Gulf Coast University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 28, 2026, 1:33 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Rare and Undiagnosed Disease Research Biorepository

NCT04703179
View directory record Official record
Conditions
Undiagnosed Disease, Rare Diseases
Interventions
Genetic test evaluation
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease

NCT01476696
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Prasugrel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
9
States / cities
Oakland, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 28, 2026, 1:33 AM EDT
Recruiting Phase 3 Interventional

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

NCT07218796
View directory record Official record
Conditions
Cataract, Glaucoma, Ocular Hypertension
Interventions
Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
Drug · Device
Lead sponsor
SpyGlass Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 28, 2026, 1:33 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

NCT00305162
View directory record Official record
Conditions
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Interventions
Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
8,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study

NCT02542462
View directory record Official record
Conditions
Intussusception, Rotavirus Infections
Interventions
Rotarix®,, Rotarix®, with other routine vaccines, RotaTeq®,, RotaTeq®, with other routine vaccines
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
42 Days to 90 Days
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 28, 2026, 1:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders

NCT02591446
View directory record Official record
Conditions
Autism Spectrum Disorder, Intellectual Disability
Interventions
Not listed
Lead sponsor
Rhode Island Hospital
Other
Eligibility
6 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 28, 2026, 1:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Anatomical and Functional Imaging Correlates of Chronic Pain in Cerebral Palsy

NCT05197946
View directory record Official record
Conditions
Cerebral Palsy, Chronic Pain
Interventions
MRI
Diagnostic Test
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
4
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV

NCT00926146
View directory record Official record
Conditions
Hepatitis B, Hepatitis C, HIV, HIV Infections
Interventions
NCMIT, SCMIT
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 39 Years · Male only
Enrollment
451 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months

NCT00792103
View directory record Official record
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Not applicable Interventional

Effectiveness of Coping Training for People With HIV Experiencing Treatment Side Effects (The Balance Project)

NCT00643903
View directory record Official record
Conditions
HIV Infections
Interventions
Cognitive behavioral coping effectiveness training, Standard care, Single group workshop on coping effectiveness training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 28, 2026, 1:33 AM EDT
Terminated Phase 4 Interventional Results available

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

NCT04997161
View directory record Official record
Conditions
Hyperkalaemia
Interventions
Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

NCT02867761
View directory record Official record
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Indacaterol/Glycopyrrolate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

NCT05764161
View directory record Official record
Conditions
Prurigo Nodularis
Interventions
Ruxolitinib Cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Arkansas City, Arkansas • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 28, 2026, 1:33 AM EDT
Not listed Not applicable Interventional

Addressing Traumatic Stress Symptoms in Children

NCT03334942
View directory record Official record
Conditions
Violence, Non-accidental, Posttraumatic Stress Disorder, Parent-Child Relations, Assault, Youth
Interventions
Child and Family Traumatic Stress Intervention
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Not applicable Interventional Results available

Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System

NCT02041286
View directory record Official record
Conditions
Diabetes
Interventions
Karajishi Contour Investigational BG Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 4 Interventional Results available

The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria

NCT01551186
View directory record Official record
Conditions
Infectious Disease of Digestive Tract
Interventions
Lactobacillus rhamnosus GG
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 28, 2026, 1:33 AM EDT
Completed Phase 2 Interventional Results available

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786
View directory record Official record
Conditions
AL Amyloidosis
Interventions
NEOD001, Placebo
Drug
Lead sponsor
Prothena Biosciences Ltd.
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 28, 2026, 1:33 AM EDT
Not listed No phase listed Observational

Risk Factors in Early Multiple Sclerosis

NCT03586986
View directory record Official record
Conditions
Multiple Sclerosis, Magnetic Resonance Imaging, Biomarkers, Clinically Isolated Syndrome, Radiologically Isolated Syndrome
Interventions
Brain MRI
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
300 participants
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 28, 2026, 1:33 AM EDT
Terminated Not applicable Interventional

Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors

NCT01679470
View directory record Official record
Conditions
Primary or Metastatic Lung Tumors
Interventions
AuroLase Therapy
Device
Lead sponsor
Nanospectra Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 28, 2026, 1:33 AM EDT